Experimental Hematology
Volume 37, Issue 7 , Pages 784-790 , July 2009

Proteomics-based prediction of clinical response in acute myeloid leukemia

  • Maher Albitar

      Affiliations

    • Quest Diagnostics Nichols Institute, San Juan Capistrano, Calif., USA
    • Corresponding Author InformationOffprint requests to: Maher Albitar, M.D., Quest Diagnostics, Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA 92690-6130
    • ,
  • Steven J. Potts

      Affiliations

    • Aperio Technologies, Vista, Calif., USA
    • ,
  • Francis J. Giles

      Affiliations

    • Division of Hematology, Cancer Therapy and Research Center, University of Texas, Health Science Center, San Antonio, Tex., USA
    • ,
  • Susan O'Brien

      Affiliations

    • Leukemia Department, M.D. Anderson Cancer Center, University of Texas, Houston, Tex., USA
    • ,
  • Iman Jilani

      Affiliations

    • Quest Diagnostics Nichols Institute, San Juan Capistrano, Calif., USA
    • ,
  • Amber C. Donahue

      Affiliations

    • Quest Diagnostics Nichols Institute, San Juan Capistrano, Calif., USA
    • ,
  • Elihu H. Estey

      Affiliations

    • Leukemia Department, M.D. Anderson Cancer Center, University of Texas, Houston, Tex., USA
    • ,
  • Hagop Kantarjian

      Affiliations

    • Leukemia Department, M.D. Anderson Cancer Center, University of Texas, Houston, Tex., USA

Received 28 June 2008 ,Revised 27 January 2009 ,Accepted 4 March 2009.

References 

  1. Stone RM, O'Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2004;98–117
  2. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322–2333
  3. Amin HM, Yang Y, Shen Y, et al. Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias. Leukemia. 2005;19:1567–1572
  4. Albitar M, Do KA, Johnson MM, et al. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer. 2004;101:999–1008
  5. Giles FJ, Vose JM, Do KA, et al. Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease. Br J Haematol. 2003;123:850–857
  6. Jilani I, Estey E, Manshuri T, et al. Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA. Leukemia. 2003;17:114–119
  7. Manshouri T, Do KA, Wang X, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood. 2003;101:2507–2513
  8. Rogers A, Joe Y, Manshouri T, et al. Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia. Blood. 2004;103:2799–2801
  9. Albitar M, Potts SJ, Giles FJ, et al. Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia. Cancer. 2006;106:1587–1594
  10. Czibere A, Grall F, Aivado M. Perspectives of proteomics in acute myeloid leukemia. Expert Rev Anticancer Ther. 2006;6:1663–1675
  11. Kiehntopf M, Siegmund R, Deufel T. Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations. Clin Chem Lab Med. 2007;45:1435–1449
  12. Anderson NL, Polanski M, Pieper R, et al. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics. 2004;3:311–326
  13. Chertov O, Simpson JT, Biragyn A, Conrads TP, Veenstra TD, Fisher RJ. Enrichment of low-molecular-weight proteins from biofluids for biomarker discovery. Expert Rev Proteomics. 2005;2:139–145
  14. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature. 2008;452:571–579
  15. Wiemer JC, Prokudin A. Bioinformatics in proteomics: application, terminology, and pitfalls. Pathol Res Pract. 2004;200:173–178
  16. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642–4649
  17. Lightfoot J, Hitzler JK, Zipursky A, Albert M, Macgregor PF. Distinct gene signatures of transient and acute megakaryoblastic leukemia in Down syndrome. Leukemia. 2004;18:1617–1623
  18. Aivado M, Spentzos D, Germing U, et al. Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. Proc Natl Acad Sci U S A. 2007;104:1307–1312
  19. Chen G, Gharib TG, Huang CC, et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics. 2002;1:304–313

PII: S0301-472X(09)00129-5

doi: 10.1016/j.exphem.2009.03.011

Experimental Hematology
Volume 37, Issue 7 , Pages 784-790 , July 2009

Article Tools

* Image Usage & Resolution